U.S. Markets closed

Acadia soars on early drug application

Jon "DRJ" Najarian (ask-drj@optionmonster.com)

Parkinson's Treatment by 2015?

Acadia Pharmaceuticals said it will seek early approval of its pimavanserin drug for the treatment of Parkinson's disease. It will no longer carry out an additional phase III trial that was slated to begin this month. ACAD explodes higher by 44 percent before the bell on my tradeMONSTER platform.

Fortinet Earnings, Revenue Miss

Fortinet earned just $0.10 on revenue of $134 million to $136 million, according to a preliminary release. Analysts were looking for $0.12 and $140 million, respectively. The company also lowered its projected billings as it struggled to close deals. FTNT drops 17 percent in early trading.

Zumiez Reports Strong Monthly Sales

Zumiez reported a 2.1 percent gain in same-store sales for the month of March, while the Street had forecast a decline of 7.5 percent. That beat has ZUMZ higher by more than 9 percent in the premarket.

More From optionMONSTER